Silence Therapeutics (SLN) Cash from Operations: 2020-2025
Historic Cash from Operations for Silence Therapeutics (SLN) over the last 6 years, with Sep 2025 value amounting to -$10.9 million.
- Silence Therapeutics' Cash from Operations rose 57.43% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$57.3 million, marking a year-over-year decrease of 23.95%. This contributed to the annual value of -$67.6 million for FY2024, which is 36.75% down from last year.
- Latest data reveals that Silence Therapeutics reported Cash from Operations of -$10.9 million as of Q3 2025, which was up 49.98% from -$21.8 million recorded in Q2 2025.
- In the past 5 years, Silence Therapeutics' Cash from Operations ranged from a high of $36.4 million in Q2 2021 and a low of -$27.5 million during Q4 2024.
- Over the past 3 years, Silence Therapeutics' median Cash from Operations value was -$12.3 million (recorded in 2025), while the average stood at -$15.4 million.
- As far as peak fluctuations go, Silence Therapeutics' Cash from Operations surged by 73.28% in 2021, and later tumbled by 429.09% in 2022.
- Over the past 5 years, Silence Therapeutics' Cash from Operations (MRQ) stood at -$3.0 million in 2021, then plummeted by 429.09% to -$15.7 million in 2022, then crashed by 42.66% to -$22.4 million in 2023, then dropped by 22.48% to -$27.5 million in 2024, then skyrocketed by 60.34% to -$10.9 million in 2025.
- Its last three reported values are -$10.9 million in Q3 2025, -$21.8 million for Q2 2025, and -$12.3 million during Q1 2025.